115 related articles for article (PubMed ID: 12717077)
1. A novel radiopharmaceutical for detection of malignant melanoma, based on melanin formation: 3-iodo-4-hydroxyphenyl-L-cysteine.
Nishii R; Kawai K; Garcia Flores L; Kataoka H; Jinnouchi S; Nagamachi S; Arano Y; Tamura S
Nucl Med Commun; 2003 May; 24(5):575-82. PubMed ID: 12717077
[TBL] [Abstract][Full Text] [Related]
2. Development of radioiodine-labeled 4-hydroxyphenylcysteamine for specific diagnosis of malignant melanoma.
Kobayashi M; Nishii R; Shikano N; Flores LG; Mizutani A; Ogai K; Sugama J; Nagamachi S; Kawai K
Nucl Med Biol; 2015 Jun; 42(6):536-40. PubMed ID: 25744361
[TBL] [Abstract][Full Text] [Related]
3. [Development of targeted chemoradiotherapy for malignant melanoma by exploitation of metabolic pathway].
Jimbow K
Hokkaido Igaku Zasshi; 1998 Mar; 73(2):105-10. PubMed ID: 9612704
[TBL] [Abstract][Full Text] [Related]
4. Development of radioiodine labeled acetaminophen for specific, high-contrast imaging of malignant melanoma.
Zhu WJ; Kobayashi M; Yamada K; Nishi K; Takahashi K; Mizutani A; Nishii R; Flores LG; Shikano N; Kunishima M; Kawai K
Nucl Med Biol; 2018 Apr; 59():16-21. PubMed ID: 29413752
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and characterization of a novel radioiodinated phenylacetamide and its homolog as theranostic agents for malignant melanoma.
Chang CC; Chang CH; Shen CC; Chen CL; Liu RS; Lin MH; Wang HE
Eur J Pharm Sci; 2016 Jan; 81():201-9. PubMed ID: 26517961
[TBL] [Abstract][Full Text] [Related]
6. Radioiodine-labelled alpha-methyl-tyrosine in malignant melanoma: cell culture studies and results in patients.
Böni R; Steinert H; Huch Böni R; Von Schulthess GK; Meyer J; Dummer R; Burg G; Westera G
Br J Dermatol; 1997 Jul; 137(1):96-100. PubMed ID: 9274632
[TBL] [Abstract][Full Text] [Related]
7. 123/125I-labelled 2-iodo-L: -phenylalanine and 2-iodo-D: -phenylalanine: comparative uptake in various tumour types and biodistribution in mice.
Kersemans V; Cornelissen B; Kersemans K; Bauwens M; Dierckx RA; De Spiegeleer B; Mertens J; Slegers G
Eur J Nucl Med Mol Imaging; 2006 Aug; 33(8):919-27. PubMed ID: 16572305
[TBL] [Abstract][Full Text] [Related]
8. Biodistribution of two (131)I-IMBA preparations, differently labelled, in mice with experimental B16 melanoma tumours.
Janczak M; Kapuściński J; Olasik EM; Rózalski M; Płachcińska A; Kuśmierek J
Nucl Med Rev Cent East Eur; 2008; 11(2):48-52. PubMed ID: 19585454
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of iodine-123-IMBA for melanoma imaging.
Nicholl C; Mohammed A; Hull WE; Bubeck B; Eisenhut M
J Nucl Med; 1997 Jan; 38(1):127-33. PubMed ID: 8998166
[TBL] [Abstract][Full Text] [Related]
10. 5-[123I/125I]iodo-2'-deoxyuridine in metastatic lung cancer: radiopharmaceutical formulation affects targeting.
Semnani ES; Wang K; Adelstein SJ; Kassis AI
J Nucl Med; 2005 May; 46(5):800-6. PubMed ID: 15872354
[TBL] [Abstract][Full Text] [Related]
11. [Utilization of melanin precursors for experimental chemotherapy of malignant melanoma].
Jimbow K; Miura S; Ito Y; Kasuga T; Ito S
Gan To Kagaku Ryoho; 1984 Oct; 11(10):2125-32. PubMed ID: 6435538
[TBL] [Abstract][Full Text] [Related]
12. S-11C-methyl-L-cysteine: a new amino acid PET tracer for cancer imaging.
Deng H; Tang X; Wang H; Tang G; Wen F; Shi X; Yi C; Wu K; Meng Q
J Nucl Med; 2011 Feb; 52(2):287-93. PubMed ID: 21233188
[TBL] [Abstract][Full Text] [Related]
13. Lack of expression of dopamine D2 receptors in malignant melanoma: evidence for interaction of iodobenzofurans with melanin.
Böni R; Steinert H; Böni RA; Lichtensteiger W; Dummer R; Hartman DS; von Schulthess GK; Burg G; Westera G
Dermatology; 1996; 193(3):198-202. PubMed ID: 8944340
[TBL] [Abstract][Full Text] [Related]
14. In vivo characterization of 123/125I-2-iodo-L-phenylalanine in an R1M rhabdomyosarcoma athymic mouse model as a potential tumor tracer for SPECT.
Kersemans V; Cornelissen B; Kersemans K; Bauwens M; Achten E; Dierckx RA; Mertens J; Slegers G
J Nucl Med; 2005 Mar; 46(3):532-9. PubMed ID: 15750170
[TBL] [Abstract][Full Text] [Related]
15. Preparation and biologic evaluation of a novel radioiodinated benzylpiperazine, 123I-MEL037, for malignant melanoma.
Pham TQ; Berghofer P; Liu X; Greguric I; Dikic B; Ballantyne P; Mattner F; Nguyen V; Loc'h C; Katsifis A
J Nucl Med; 2007 Aug; 48(8):1348-56. PubMed ID: 17631542
[TBL] [Abstract][Full Text] [Related]
16. Secondary ion mass spectrometry as a tool for investigating radiopharmaceutical distribution at the cellular level: the example of I-BZA and (14)C-I-BZA.
Chéhadé F; de Labriolle-Vaylet C; Moins N; Moreau MF; Papon J; Labarre P; Galle P; Veyre A; Hindié E
J Nucl Med; 2005 Oct; 46(10):1701-6. PubMed ID: 16204721
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, characterization and comparative biodistribution study of a new series of p-iodine-125 benzamides as potential melanoma imaging agents.
Moins N; Papon J; Seguin H; Gardette D; Moreau MF; Labarre P; Bayle M; Michelot J; Gramain JC; Madelmont JC; Veyre A
Nucl Med Biol; 2001 Oct; 28(7):799-808. PubMed ID: 11578901
[TBL] [Abstract][Full Text] [Related]
18. A gallium-labeled DOTA-alpha-melanocyte- stimulating hormone analog for PET imaging of melanoma metastases.
Froidevaux S; Calame-Christe M; Schuhmacher J; Tanner H; Saffrich R; Henze M; Eberle AN
J Nucl Med; 2004 Jan; 45(1):116-23. PubMed ID: 14734683
[TBL] [Abstract][Full Text] [Related]
19. 123I-N-(2-diethylaminoethyl)-2-iodobenzamide: a potential imaging agent for cutaneous melanoma staging.
Moins N; D'Incan M; Bonafous J; Bacin F; Labarre P; Moreau MF; Mestas D; Noirault E; Chossat F; Berthommier E; Papon J; Bayle M; Souteyrand P; Madelmont JC; Veyre A
Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1478-84. PubMed ID: 12397467
[TBL] [Abstract][Full Text] [Related]
20. Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting.
Haubner R; Wester HJ; Reuning U; Senekowitsch-Schmidtke R; Diefenbach B; Kessler H; Stöcklin G; Schwaiger M
J Nucl Med; 1999 Jun; 40(6):1061-71. PubMed ID: 10452325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
